ReviewUnited European gastroenterology journal2018
Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis.
Review in United European gastroenterology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Guideline
- Pancreatic cysts on MRI: prevalence and factors associated with reporting.Abdominal radiology (New York) · 2026Article
- Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations.Communications medicine · 2026Review
- Hereditary Pancreatic Cancer: Genetic Risk, Surveillance Strategies, and Therapeutic Implications.International journal of molecular sciences · 2026Review
- Cost-effectiveness of pancreatic cancer screening: Time for a more tailored approach.United European gastroenterology journal · 2023Article
- Immunotherapy in combination with chemotherapy for Peutz-Jeghers syndrome with advanced cervical cancer: A case report.World journal of gastrointestinal surgery · 2023Article
- Review
- Article
- Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment.Gastroenterology · 2022Review
- Peutz-Jeghers Syndrome and the Role of Imaging: Pathophysiology, Diagnosis, and Associated Cancers.Cancers · 2021Review
- Early Detection of Pancreatic Cancer: Risk Factors and the Current State of Screening Modalities.Gastroenterology & hepatology · 2021Article
- Lack of association of CD44-rs353630 and CHI3L2-rs684559 with pancreatic ductal adenocarcinoma survival.Scientific reports · 2021Article
- Screening for pancreatic cancer-a compelling challenge.Hepatobiliary surgery and nutrition · 2021Article
- The Management of Peutz-Jeghers Syndrome: European Hereditary Tumour Group (EHTG) Guideline.Journal of clinical medicine · 2021Review
- Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer.JCO precision oncology · 2021Article
- Review
- Diagnostic delay does not influence survival of pancreatic cancer patients.United European gastroenterology journal · 2020Article
- Long-term positive psychological outcomes in an Australian pancreatic cancer screening program.Familial cancer · 2020Article
- COMMUNI.Frontiers in medicine · 2020Article
- Familial Pancreatic Cancer: Current Perspectives.Cancer management and research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundData on surveillance for pancreatic ductal adenocarcinoma (PDAC) in high-risk individuals (HRIs) with "familial pancreatic cancer" (FPC) and specific syndromes are limited and heterogeneous.
objectiveWe conducted a systematic review and meta-analysis of PDAC surveillance studies in HRIs.
methodsPrevalence of solid/cystic pancreatic lesions and of lesions considered a successful target of surveillance (proven resectable PDAC and high-grade precursors) was pooled across studies. The rate of lesions diagnosed by endoscopic ultrasonography (EUS)/magnetic resonance imaging (MRI) and across different HRI groups was calculated.
resultsSixteen studies incorporating 1588 HRIs were included. The pooled prevalence of pancreatic solid and cystic lesions was 5.8% and 20.2%, respectively. The pooled prevalence of patients with lesions considered a successful target of surveillance was 3.3%, being similar to EUS or MRI and varying across subgroups, being 3% in FPC, 4% in hereditary pancreatitis, 5% in familial melanoma, 6.3% in hereditary breast/ovarian cancer, and 12.2% in Peutz-Jeghers syndrome. The pooled estimated rate of lesions considered a successful target of surveillance during follow-up was 5/1000 person-years.
conclusionSurveillance programs identify successful target lesions in 3.3% of HRIs with a similar yield of EUS and MRI and an annual risk of 0.5%. A higher rate of target lesions was reported in HRIs with specific DNA mutations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.